Loading
Liver Disease Diagnosis and Treatment / Diabetes, Cardiovascular Risks, and Lipoproteins / Adipokines, Inflammation, and Metabolic Diseases · Journal article
Metabolites · August 11, 2026
Encouraging direction, but not yet definitive.
This cross-sectional study characterises biomarker patterns and cardiometabolic indices across metabolic syndrome phenotypes in a Slovak cohort, finding that obesity status modifies body composition and hepatic markers but not lipid atherogenicity or LDL subfraction distribution. The work supports the existence of metabolically unhealthy normal-weight individuals and identifies novel indices (VAI, TyG variants, LAP, AIP, CMI) that correlate with visceral adiposity and atherogenic lipid profiles, but lacks prospective validation or outcome prediction data.
Cross-sectional observational study. 188 Slovak adults; groups stratified by metabolic syndrome status and obesity status (controls, normal-weight MetS, overweight/obese MetS); specific age range and gender distribution not stated in abstract.. n = 188. Slovakia (single-centre study; specific location(s) not named)..
Participants with MetS had significantly greater adiposity, visceral fat accumulation, atherogenic lipid alterations, elevated inflammatory and liver biomarkers, higher blood pressure, and increased cardiometabolic indices (p < 0.05) compared with controls. Within the MetS group, overweight/obese participants exhibited greater visceral adiposity and higher liver enzyme concentrations, whereas most lipid parameters and LDL subfraction distribution were comparable between weight groups. VAI, TyG, TyG-BMI, TyG-WC, TyG-WHtR, LAP, AIP, and CMI showed strong correlations with visceral adiposity, triglycerides, atherogenic LDL subfractions, and smaller LDL particle size.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should consider that LDL-C concentration alone may underestimate atherogenic risk in metabolic syndrome, and that novel indices integrating visceral adiposity and triglyceride metabolism may improve stratification. However, prospective validation linking these indices to clinical outcomes is needed before recommending widespread adoption.
Cross-sectional study in a single population identifying biomarker patterns and novel indices for cardiometabolic risk assessment in metabolic syndrome, with clear descriptive findings but limited by design and no intervention or outcome prediction validation.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should consider that LDL-C concentration alone may underestimate atherogenic risk in metabolic syndrome, and that novel indices integrating visceral adiposity and triglyceride metabolism may improve stratification. However, prospective validation linking these indices to clinical outcomes is needed before recommending widespread adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Metabolic syndrome (MetS) is associated with increased cardiometabolic risk, although substantial metabolic abnormalities may also occur in individuals with normal body weight. This study compared anthropometric characteristics, body composition, lipid profile, LDL subfractions, inflammatory markers, liver biomarkers, and novel cardiometabolic indices in participants with MetS according to obesity status and characterized the metabolic phenotype of normal-weight participants with MetS. Methods: This cross-sectional study included 188 Slovak adults. Anthropometric, biochemical, lipoprotein, inflammatory, liver function, and cardiometabolic parameters were assessed. Group differences were analyzed using the Mann–Whitney U test, and associations were evaluated by Spearman’s correlation analysis. Results: Compared with controls, participants with MetS had significantly greater adiposity, visceral fat accumulation, atherogenic lipid alterations, elevated inflammatory and liver biomarkers, higher blood pressure, and increased cardiometabolic indices (p < 0.05). Within the MetS group, overweight/obese participants exhibited greater visceral adiposity and higher liver enzyme concentrations, whereas most lipid parameters, LDL subfraction distribution, and several cardiometabolic indices were comparable between weight groups. VAI, TyG, TyG-BMI, TyG-WC, TyG-WHtR, LAP, AIP, and CMI showed strong correlations with visceral adiposity, triglycerides, atherogenic LDL subfractions, and smaller LDL particle size. Conclusions: Obesity worsens body composition and hepatic dysfunction in MetS but has limited impact on several metabolic and atherogenic characteristics. LDL-C concentration alone may not sufficiently reflect the true atherogenic risk. These findings support the metabolically unhealthy normal-weight phenotype and highlight the value of novel cardiometabolic indices and LDL subfraction analysis for improved cardiometabolic risk assessment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.